Table 2.
Receiver operating characteristic curve analysis and three‐year PFS from related parameters
| Variables | AUC | Cutoff value | Sensitivity (%) | Specificity (%) | Three‐year PFS (above vs. below cutoffs) (%) |
|---|---|---|---|---|---|
| SUVmax0 | 0.573 | – | – | – | – |
| TMTV0 | 0.745 | 80.74 | 91.3 | 56.5 | 56.3 vs. 94.6 |
| TLG0 | 0.738 | 1036.61 | 91.3 | 56.5 | 56.3 vs. 94.6 |
| SUVmax1 | 0.751 | 3.85 | 69.6 | 74.2 | 50.0 vs. 86.8 |
| TMTV1 | 0.735 | 4.32 | 60.9 | 87.1 | 36.4 vs. 85.7 |
| TLG1 | 0.737 | 14.07 | 60.9 | 85.5 | 39.1 vs. 85.5 |
| %ΔSUVmax | 0.715 | 86.02 | 87 | 51.6 | 91.4 vs. 60.0 |
| %ΔTMTV | 0.723 | 99.22 | 60.9 | 85.5 | 85.5 vs. 39.1 |
| %ΔTLG | 0.727 | 99.86 | 60.9 | 83.9 | 85.2 vs. 41.7 |
| ΔSUVmax | 0.446 | – | – | – | – |
| ΔTMTV | 0.689 | – | – | – | – |
| ΔTLG | 0.683 | – | – | – | – |
| NCCN‐IPI (>3 vs. ≤3) | 52.8 vs. 87.8 |
AUC, area under the receiver operating characteristic curve; MTV, metabolic tumor volume; NCCN‐IPI, National Comprehensive Cancer Network International Prognostic Index; PFS, progression‐free survival; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis. The subscripts 0 and 1 represent baseline and interim measures, respectively.